COMMUNIQUÉS West-GlobeNewswire

-
CorMedix Inc. Announces Pricing of Public Offering of Common Stock
27/06/2025 -
Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
27/06/2025 -
Ultragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome
27/06/2025 -
Results of Annual General Meeting
27/06/2025 -
Helius Medical Technologies Announces Reverse Stock Split
27/06/2025 -
VigRX Organic Bio Maca Supplement: Experts Discuss Science Behind Beginner’s Guide to Choose Best Maca Root Supplement For Men & Women
27/06/2025 -
Kratom Brand, Happy Go Leafy Announces 2025 Product Line Featuring New Strains for Pain Relief, Energy, and Mood Enhancement
27/06/2025 -
Clearmind Medicine Expands Global Clinical Trial Targeting Multibillion-Dollar Alcohol Use Disorder Market
27/06/2025 -
ALPHA PRO TECH, LTD. ANNOUNCES $2 MILLION EXPANSION OF SHARE REPURCHASE PROGRAM
27/06/2025 -
Channel Therapeutics Announces Reverse Common Stock Split in Conjunction with the Close of the Merger with Pelthos Therapeutics and Concurrent $50.1 Million Private Placement
27/06/2025 -
Safety Shot Completes Acquisition of Yerbae Brands Corp.
27/06/2025 -
New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA
27/06/2025 -
Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit
27/06/2025 -
Eton Pharmaceuticals Announces Addition to Russell 2000® and Russell 3000® Indexes
27/06/2025 -
Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines’ Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung Cancer
27/06/2025 -
BioCryst Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 Million
27/06/2025 -
FOXO TECHNOLOGIES INC. DESIGNATES NEW SERIES OF PREFERRED STOCK TO BE USED FOR ACQUISITIONS
27/06/2025 -
Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right
27/06/2025 -
HCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid Tumors
27/06/2025
Pages